|Bid||8.51 x 4000|
|Ask||9.53 x 900|
|Day's Range||9.34 - 9.68|
|52 Week Range||6.22 - 25.29|
|Beta (3Y Monthly)||4.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2017 - Mar 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.67|
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking i...
Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today that an overview of the company's business strategy and development-stage programs will be given at the H.C. Wainwright Global Life Sciences Conference being held in London. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology.
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Spectrum Pharma (SPPI) withdraws the BLA seeking approval for Rolontis, as the FDA requests for additional manufacturing-related data.
Spectrum Pharmaceuticals Inc. shares slid 7.6% in premarket trade Friday, after the company said it is withdrawing its Biologics License Application for Rolontis after the U.S. Food and Drug Administration asked for manufacturing-related information. The company said the decision was made because it needs more time to comply with the FDA request and that it will resubmit a BLA as soon as possible. "We are continuing to have productive discussions with the FDA and will deliver the additional information needed to support the application, " CEO Joe Turgeon said in a statement. Rolontis is a treatment for the management of chemotherapy-induced neutropenia in patients undergoing myelosuppressive chemotherapy. Neutropenia is a common side effect of myelosuppressive chemotherapy that increases the risk of infection and reduces patients' ability to fight infection. Spectrum shares have fallen 44% in the last 12 months, while the S&P 500 has gained 2.2%.
Spectrum Pharmaceuticals, Inc. (SPPI) announced today that due to the U.S. Food and Drug Administration’s (FDA) request for additional manufacturing-related information for ROLONTIS, the company has voluntarily withdrawn its Biologics License Application (BLA). Spectrum plans to resubmit a revised BLA as soon as possible. The FDA did not cite concerns related to the pre-clinical and clinical modules of the BLA or the need for additional clinical studies.
Spectrum Pharmaceuticals (SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the Oppenheimer 29th Annual Healthcare Conference being held in New York. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology.
Ligand Pharmaceuticals (LGND) announces sale of all rights to Novartis' Promacta, including royalty payments on global sales, to Royalty Pharma.
Spectrum Pharmaceuticals, Inc. (SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today completed the sale of its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C., a step-down subsidiary of Aurobindo Pharma Limited, India. “The completion of this sale marks a significant pivot point in Spectrum’s history as we focus our efforts on our two promising late stage assets, ROLONTIS® and poziotinib,” stated Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. In addition, the company is eligible to receive up to $140 million in milestone payments.
HENDERSON, Nev.-- -- Poziotinib enrollment completed in previously treated EGFR cohort of ZENITH20 trial; topline results are expected in Q4 2019 ROLONTIS ® Biologics License Application was submitted to the FDA Q4 Revenues were $29.4 million, including $28.0 million in product sales; full year revenues were $109.3 million including $104.5 million in product sales Spectrum Pharmaceuticals, Inc. , a ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We've lost count of how many times insiders have accumulatedRead More...
Spectrum Pharmaceuticals (SPPI), announced today it will host a conference call with management to discuss the fourth quarter and full year 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, February 28, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.
Spectrum Pharmaceuticals (SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum | Oncology Day being held in New York. The company presentation is on Thursday, February 14, 2019, at 9:30 AM ET. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com.
popped Thursday after the company announced that it was selling its marketed portfolio of seven Food and Drug Administration-approved products to Acrotech Biopharma for $160 million up front, with a potential for another $140 million in regulatory and sales-based milestones. The company will reduce its staff size by about 40% as a result of the deal, with the impacted staff transitioning over to Acrotech. "This divestiture marks a major strategic shift for Spectrum to ensure laser-focus on novel, oncology drug development and commercialization," said Joe Turgeon, president and CEO of Spectrum Pharmaceuticals.
HENDERSON, Nev.-- -- Spectrum will receive $160 million in an upfront cash payment and up to $140 million in regulatory and sales-based milestones Staff size will be reduced by approximately 40 percent with the majority of impacted staff transitioning to Acrotech Spectrum will retain a core group of commercial talent to lead the launch of ROLONTIS ® and poziotinib Management to host a webcast on ...
Spectrum Pharma (SPPI) completes enrollment in the first cohort of a phase II study on poziotinib for previously treated NSCLC patients with EGFR exon 20 insertion mutations. Shares rise.
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced full enrollment of cohort 1 (N=87) for previously treated Non-Small Cell Lung Cancer (NSCLC) patients with EGFR exon 20 insertion mutations with sites across the U.S., Europe, and Canada. The EGFR previously treated cohort is part of the ZENITH20 trial – an open-label, multi-center, global Phase 2 trial evaluating NSCLC patients with EGFR or HER2 exon 20 insertion mutations. “The rapid rate at which we enrolled our Phase 2 previously treated EGFR exon 20 insertion mutations cohort speaks to the critical unmet medical need and demonstrates that the poziotinib program is aggressively advancing,” said Joe Turgeon, President and Chief Executive Officer of Spectrum Pharmaceuticals.
Spectrum Pharma (SPPI) petitions for a BLA to the FDA regarding its lead pipeline candidate, Rolontis, to address chemotherapy-induced neutropenia in patients with breast cancer.